A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  New England Journal of Medicine

• Publication date

  2006-03-09

• Fields of study

  Medicine

• Identifiers
  DOI 10.1056/NEJMOA051285PMID 16525137
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level.

  2006cited by this paper
• Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B.

  2005cited by this paper
• Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B.

  2005cited by this paper
• A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients.

  2005cited by this paper
• Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men.

  2005cited by this paper
• Lamivudine for patients with chronic hepatitis B and advanced liver disease.

  2004cited by this paper
• Clinical Emergence of Entecavir-Resistant Hepatitis B Virus Requires Additional Substitutions in Virus Already Resistant to Lamivudine

  2004cited by this paper
• AASLD single‐topic research conference on hepatocellular carcinoma: Conference proceedings

  2004cited by this paper
• Four years of lamivudine treatment in Chinese patients with chronic hepatitis B

  2004cited by this paper
• Lamivudine and Famciclovir resistant hepatitis B virus associated with fatal hepatic failure.

  2003cited by this paper
• Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.

  2003cited by this paper
• Asian‐Pacific consensus statement on the management of chronic hepatitis B: An update *

  2003cited by this paper
• Histological outcome during long-term lamivudine therapy.

  2003cited by this paper
• Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection.

  2002cited by this paper
• Impact of YMDD mutations during lamivudine therapy in patients with chronic hepatitis B.

  2001cited by this paper
• Long-term entecavir treatment results in sustained antiviral efficacy and prolonged life span in the woodchuck model of chronic hepatitis infection.

  2001cited by this paper
• Hepatitis B virus infection: resistance to antiviral agents.

  2001cited by this paper
• Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: Results after 3 years of therapy

  2001cited by this paper
• Long‐term therapy of chronic hepatitis B with lamivudine

  2000cited by this paper
• Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

  2000cited by this paper
• Lamivudine as initial treatment for chronic hepatitis B in the United States.

  1999cited by this paper
• Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy

  1999cited by this paper
• A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

  1998cited by this paper
• Hepatitis B virus infection.

  1998cited by this paper
• Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus

  1997cited by this paper
• Hepatitis B virus infection.

  1997cited by this paper
• An alternative to the use of two-sided tests in clinical trials.

  1996cited by this paper
• The treatment effect of alpha interferon in chronic hepatitis B is independent of pre-treatment variables. Results based on individual patient data from 10 clinical controlled trials. European Concerted Action on Viral Hepatitis (Eurohep).

  1994cited by this paper
• Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis

  1981cited by this paper

• Predicting loss of hepatitis B surface antigen and evaluating the durability of functional cure induced by pegylated interferon alpha: insights from a real-world study

  2026influential citation
• Machine Learning-Based Prediction of Decompensation in Hepatitis B Virus-Related Cirrhosis

  2025cites this paper
• Need of Treatment Modification During Entecavir Therapy in Patients with Chronic Hepatitis B: Long-Term Follow-Up Results for 120 Months

  2025influential citation
• Pathogenesis, prevention, and therapeutic advances in hepatitis B, C, and D

  2025cites this paper
• Entecavir for children and adults with chronic hepatitis B.

  2025cites this paper
• Efficacy and Safety of Tenofovir Plus Entecavir Combination Therapy Versus Tenofovir Monotherapy in Chronic Hepatitis B Virus Patients With Resistance or Partial Response to Entecavir: A Systematic Review and Meta-analysis.

  2025cites this paper
• Glomerulonephritis, the Most Common Extrahepatic Manifestation Caused by Hepatitis B Virus Infection: Possible Pathogenesis and Therapeutic Approaches

  2025cites this paper
• EASL Clinical Practice Guidelines on the management of hepatitis B virus infection.

  2025cites this paper
• Entecavir in Hepatitis B Treatment: A 25-Year Bibliometric Journey (2001-2025) Through Trends, Themes, and Therapeutic Advances

  2025cites this paper
• A predictive model for functional cure in chronic HBV patients treated with pegylated interferon alpha: a comparative study of multiple algorithms based on clinical data

  2024cites this paper
• Risk Factors for Development of Cirrhosis in Chronic Viral Hepatitis B Patients Who Had Persistent Viral Suppression With Antiviral Therapy.

  2024cites this paper
• Comparative efficacy and safety of tenofovir amibufenamide vs tenofovir alafenamide in the initial 48-week treatment of high viral load chronic hepatitis B: A single-centre retrospective study

  2024cites this paper
• The 90‐Day Survival Threshold: A Pivotal Determinant of Long‐Term Prognosis in HBV‐ACLF Patients – Insights from a Prospective Longitudinal Cohort Study

  2024cites this paper
• Real‐world safety and effectiveness of tenofovir alafenamide for 144 weeks in Japanese patients with chronic hepatitis B

  2024cites this paper
• Antiviral Therapy of Chronic Hepatitis B Virus between Present and Future

  2024cites this paper
• Mechanistic modeling to understand variability in responses to chronic Hepatitis B treatment

  2024cites this paper
• Utilization of Hepatitis B viremic donors (NAT+) leads to improved kidney transplant access for older adult recipients with little to no wait time

  2024cites this paper
• Challenges for hepatitis B control in Asia‐Pacific areas: Consolidating vaccination and rolling‐out antiviral therapies

  2024cites this paper
• Cost-effectiveness analysis of oral antiviral therapy in patients with indeterminate chronic hepatitis B infection

  2023cites this paper
• Blockade of CCR4 breaks immune tolerance in chronic hepatitis B patients by modulating regulatory pathways

  2023cites this paper
• Comparison of patients using lamivudine, entecavir, and tenofovir according to liver fibrosis markers fibrosis-4 and aspartate aminotransferase-to-platelet ratio index scores

  2023cites this paper
• Steady Decline of HBV DNA Load under NAs in Lymphoma Patients and a Higher Level of qAnti-HBc Predict HBV Reactivation

  2023cites this paper
• Factors associated with persistent positive in HBV DNA level in patients with chronic Hepatitis B receiving entecavir treatment

  2023influential citation
• Research progress on hCNT3 structure/ function and nucleoside anticancer drugs.

  2023cites this paper
• Clinical and virological characteristics of chronic hepatitis b and response to antiviral therapy

  2023cites this paper
• Impact of nucleos(t)ide analogues on the risk of hepatocellular carcinoma in chronic hepatitis B patients: A time-dependent Cox regression analysis.

  2023cites this paper
• Hepatitis B Virus Epsilon (ε) RNA Element: Dynamic Regulator of Viral Replication and Attractive Therapeutic Target

  2023cites this paper
• Deciphering the roles of myeloid derived suppressor cells in viral oncogenesis

  2023cites this paper
• Recent Efforts in Identification of Privileged Scaffolds as Antiviral Agents

  2023cites this paper
• Evaluation of alanine aminotransferase responses in chronic hepatitis B patients using entecavir or tenofovir disoproxil fumarate

  2023cites this paper
• Conserved long noncoding RNA TILAM promotes liver fibrosis through interaction with PML in hepatic stellate cells

  2023cites this paper
• Efficacy and safety of tenofovir alafenamide in patients with chronic hepatitis B exhibiting suboptimal response to entecavir

  2023cites this paper
• PREDICTION OF HEPATOCELLULAR CARCINOMA THROUGH THE MODIFIED PAGE-B SCORE (MPAGE-B) IN PATIENTS WITH CHRONIC HEPATITIS B: IT SHOULD BE USED IN CLINICAL PRACTICE?

  2023cites this paper
• Entecavir for children and adults with chronic hepatitis B

  2023cites this paper
• Management and Treatment of Patients with Chronic Hepatitis B: Towards Personalized Medicine

  2022cites this paper
• Advances in new antivirals for chronic hepatitis B

  2022cites this paper
• Special Collection: A pioneer in antiviral drug discovery and development: Commemorating John Martin-Review

  2022cites this paper
• First‐line therapies for hepatitis B in the United States: A 3‐year prospective and multicenter real‐world study after approval of tenofovir alefenamide

  2022cites this paper
• KASL clinical practice guidelines for management of chronic hepatitis B

  2022cites this paper
• Better survival of patients with hepatitis B virus-related hepatocellular carcinoma in South Korea: Changes in 16-years cohorts

  2022cites this paper
• Effect of antiviral treatment on hepatitis B virus integration and hepatocyte clonal expansion.

  2022cites this paper
• Getting to HBV cure: The promising paths forward

  2022cites this paper
• Polyarthritis presented in a patient with untreated chronic hepatitis B infection.

  2022cites this paper
• Safety, pharmacokinetics and antiviral activity of ABI‐H2158, a hepatitis B virus core inhibitor: A randomized, placebo‐controlled phase 1 study

  2022cites this paper
• The efficacy and safety of adding on or switching to peginterferon α‐2b in HBeAg‐positive chronic hepatitis B patients with long‐term entecavir treatment: a multicentre randomised controlled trial

  2022cites this paper
• HCC incidence is decreasing in Korea but increasing in elderly

  2022cites this paper
• Hepatitis B virus pre-genomic RNA and hepatitis B core-related antigen reductions at week 4 predict favourable hepatitis B surface antigen response upon long-term nucleos(t)ide analogue in chronic hepatitis B

  2022cites this paper
• Health inequalities in the management of chronic hepatitis B virus infection in patients from sub-Saharan Africa in high-income countries

  2022cites this paper
• One hundred and ninety-two weeks treatment of entecavir maleate for Chinese chronic hepatitis B predominantly genotyped B or C

  2022cites this paper
• A Semi‐mechanistic Model to Characterize the Long‐Term Dynamics of Hepatitis B Virus Markers During Treatment With Lamivudine and Pegylated Interferon

  2022cites this paper
• Adherence to Treatment with Oral Nucleoside/Nucleotide Analogs in Patients with Chronic Hepatitis B

  2022cites this paper
• Validation of Hepatocellular Carcinoma Risk Prediction Models in Patients with Hepatitis B-Related Cirrhosis

  2022cites this paper
• Clinical Trials in HDV: Measuring Success.

  2022cites this paper
• Pegylated interferon therapy-related microRNA-6126 downregulates sodium taurocholate cotransporting polypeptide expression in hepatocytes.

  2022cites this paper
• JNJ-73763989 pharmacokinetics and safety: Liver-targeted siRNAs against hepatitis B virus, in Japanese and non-Japanese healthy adults, and combined with JNJ-56136379 and a nucleos(t)ide analogue in patients with chronic hepatitis B

  2022cites this paper
• Association of Chronic Hepatitis B Infection and Antiviral Treatment With the Development of the Extrahepatic Malignancies: A Nationwide Cohort Study

  2022cites this paper
• Safety and efficacy of vebicorvir administered with entecavir in treatment-naïve patients with chronic hepatitis B virus infection.

  2022cites this paper
• Wiener klinische Wochenschrift

  2022cites this paper
• Efficacy and safety of Fuzheng Huayu tablet on persistent advanced liver fibrosis following 2 years entecavir treatment: A single arm clinical objective performance criteria trial.

  2022cites this paper
• Coinfection of Clonorchis sinensis and hepatitis B virus: clinical liver indices and interaction in hepatic cell models

  2022cites this paper
• Meta-omics characteristics of intestinal microbiota associated to HBeAg seroconversion induced by oral antiviral therapy

  2021cites this paper
• Prophylactic antiviral therapy for hepatitis B virus surface antigen‐positive patients with diffuse large B‐cell lymphoma treated with rituximab‐containing chemotherapy

  2021cites this paper
• Comparison of fibrosis regression of entecavir alone or combined with pegylated interferon alpha2a in patients with chronic hepatitis B

  2021cites this paper
• Nucleos(t)ide Therapy and Long-Term Outcomes

  2021cites this paper
• Hepatitis B Virus Covalently Closed Circular DNA Predicts Postoperative Liver Cancer Metastasis Independent of Virological Suppression

  2021cites this paper
• Randomized Controlled Study of Tenofovir versus Lamivudine Followed by Tenofovir in Severe Exacerbation of Hepatitis B

  2021cites this paper
• Acute and Chronic Hepatitis

  2021cites this paper
• Entecavir Induced Severe Myopathy: An Uncommon Side Effect

  2021cites this paper
• International cooperation on health and medical care for viral hepatitis: 30 years of activities on comprehensive viral hepatitis control of the JICA group training program for developing countries.

  2021cites this paper
• Human Hepatitis B Virus Negatively Impacts the Protective Immune Crosstalk Between Natural Killer and Dendritic Cells

  2021cites this paper
• Combination of Entecavir or Tenofovir with Pegylated Interferon-α for Long-Term Reduction in Hepatitis B Surface Antigen Levels: Simultaneous, Sequential, or Add-on Combination Therapy

  2021cites this paper
• DNA-RNA

  2021cites this paper
• What Should Be Done to Re-evaluate Cessation of Nucleos(t)ide Analog Therapy for Chronic Hepatitis B Infection?

  2021cites this paper
• Serum miR-192-5p levels predict the efficacy of pegylated interferon therapy for chronic hepatitis B

  2021cites this paper
• Drug Resistance in Liver Diseases

  2021cites this paper
• Cost-effectiveness of universal screening for chronic hepatitis B virus infection in China: an economic evaluation

  2021cites this paper
• Dual Agonist of Farnesoid X Receptor and Takeda G Protein‐Coupled Receptor 5 Inhibits Hepatitis B Virus Infection In Vitro and In Vivo

  2021cites this paper
• New Insights on Long-Term Hepatitis B Virus Responses in HIV-Hepatitis B virus Co-infected Patients: Implications for Antiretroviral Management in Hepatitis B virus-Endemic Settings.

  2021cites this paper
• HBV/HIV Coinfection: Impact on the Development and Clinical Treatment of Liver Diseases

  2021cites this paper
• SARS-CoV-2 RdRp Inhibitors Selected from a Cell-Based SARS-CoV-2 RdRp Activity Assay System

  2021cites this paper
• Expanding the Donor Pool: First Use of Hepatitis B Virus Nat Positive Solid Organ Allografts Into Seronegative Recipients

  2021cites this paper
• Safety, tolerability, pharmacokinetics, and pharmacodynamics of oral JNJ-64794964, a TLR-7 agonist, in healthy adults.

  2021cites this paper
• Trends and strategies to combat viral infections: A review on FDA approved antiviral drugs

  2021cites this paper
• Chapter XX Antiviral Treatment and Cancer Control.

  2021cites this paper
• Efficacy and safety of a nanoparticle therapeutic vaccine in patients with chronic hepatitis B: A randomized clinical trial

  2021cites this paper
• Clinical Features and Resistance to Entecavir Monotherapy of Patients with Hepatitis B

  2021cites this paper
• Leitlinienreport zur aktualisierten S3-Leitlinie der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) zur Prophylaxe, Diagnostik und Therapie der Hepatitis-B-Virusinfektion

  2021cites this paper
• “COMPARATIVE EFFICACY OF ENTECAVIR AND TENOFOVIR ALAFENAMIDE IN TREATMENT OF CHRONIC HEPATITIS-B ”

  2021cites this paper
• Toward a complete cure for chronic hepatitis B: Novel therapeutic targets for hepatitis B virus

  2021cites this paper
• Virushepatitis A, B und D

  2021cites this paper
• Comparative role of tenofovir versus entecavir for treating patients with hepatitis B virus-related acute on chronic liver failure

  2021cites this paper
• Review of Current and Potential Treatments for Chronic Hepatitis B Virus Infection.

  2021cites this paper
• Baseline serum hepatitis B core antibody level predicts HBeAg seroconversion in patients with HBeAg-positive chronic hepatitis B after antiviral treatment.

  2021cites this paper
• SIGLEC-3 (CD33) serves as an immune checkpoint receptor for HBV infection.

  2021cites this paper
• 造血干细胞移植相关乙型肝炎病毒再激活研究进展

  2021cites this paper
• Hepatitis B Virus Reactivation in Gastrointestinal Stromal Tumor Patients Treated With Imatinib

  2021cites this paper
• Blinding in Clinical Trials for Chronic Liver Diseases

  2021cites this paper
• Guidelines for Prevention and Treatment of Chronic Hepatitis B

  2021cites this paper
• An Evaluation of the Effectiveness of Entecavir in Patients with Acute Chronic Hepatitis B liver Failure

  2021cites this paper
• SASLT practice guidelines for the management of Hepatitis B virus – An update

  2021cites this paper